Multinational Association of Supportive Care in Cancer (MASCC) 2020 clinical practice recommendations for the management of severe dermatological toxicities from checkpoint inhibitors Review
| Authors: | Choi, J.; Anderson, R.; Blidner, A.; Cooksley, T.; Dougan, M.; Glezerman, I.; Ginex, P.; Girotra, M.; Gupta, D.; Johnson, D.; Shannon, V. R.; Suarez-Almazor, M.; Rapoport, B. L.; Lacouture, M. E. |
| Review Title: | Multinational Association of Supportive Care in Cancer (MASCC) 2020 clinical practice recommendations for the management of severe dermatological toxicities from checkpoint inhibitors |
| Abstract: | Immune checkpoint inhibitors (ICIs) frequently result in cutaneous immune-related adverse events (IrAEs). Although the majority of these events are mild-to-moderate in severity, up to 5% are severe, which may lead to morbidity and dose interruption or discontinuation of ICI therapy. In addition, up to 25% of dermatologic IrAEs are corticosteroid-refractory or corticosteroid-dependent. These 2020 MASCC recommendations cover the diagnosis and management of cutaneous IrAEs with a focus on moderate-to-severe and corticosteroid-resistant events. Although the usage of immune-suppressive therapy has been advocated in this setting, there is a lack of randomized clinical trial data to provide a compelling level of evidence of its therapeutic benefit. © 2020, Springer-Verlag GmbH Germany, part of Springer Nature. |
| Keywords: | pruritus; vitiligo; corticosteroids; skin rash; bullous dermatoses; cutaneous iraes; inflammatory dermatitis |
| Journal Title: | Supportive Care in Cancer |
| Volume: | 28 |
| Issue: | 12 |
| ISSN: | 0941-4355 |
| Publisher: | Springer Verlag |
| Date Published: | 2020-12-01 |
| Start Page: | 6119 |
| End Page: | 6128 |
| Language: | English |
| DOI: | 10.1007/s00520-020-05706-4 |
| PUBMED: | 32856211 |
| PROVIDER: | scopus |
| DOI/URL: | |
| Notes: | Article -- Export Date: 1 December 2020 -- Source: Scopus |
Altmetric
Citation Impact
BMJ Impact Analytics
Related MSK Work